Laboratory of Translational Cancer Genomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1665/76, Pilsen 323 00, Czech Republic.
Laboratory of Translational Cancer Genomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1665/76, Pilsen 323 00, Czech Republic.
Crit Rev Oncol Hematol. 2024 Aug;200:104391. doi: 10.1016/j.critrevonc.2024.104391. Epub 2024 May 23.
Hepatocellular carcinoma (HCC) is a severe neoplastic disease associated with high morbidity and mortality rates. HCC is often detected at advanced stages leading to ineffective curative treatments. Recently, liquid biopsy has emerged as a non-invasive method to identify highly specific HCC biomarkers in bodily fluids such as blood, serum, urine, and saliva. Circulating cell-free nucleic acids (cfNAs), particularly cell-free DNA (cfDNA) and cell-free RNA (cfRNA), have become promising candidates for biomarkers in liquid biopsy applications. While cfDNA presented significant challenges, researchers have turned their attention to cfRNA, which can be efficiently identified through various methods and is considered a potential biomarker for cancer diagnosis and prognosis. This review primarily focuses on studies related to detecting various cfRNA in body fluids as biomarkers. The aim is to provide a summary of available information to assist researchers in their investigations and the development of new diagnostic and prognostic tools.
肝细胞癌(HCC)是一种严重的肿瘤疾病,具有较高的发病率和死亡率。HCC 通常在晚期被发现,导致治疗效果不佳。最近,液体活检作为一种非侵入性方法,在血液、血清、尿液和唾液等体液中识别高度特异性 HCC 生物标志物已崭露头角。循环无细胞核酸(cfNAs),特别是无细胞 DNA(cfDNA)和无细胞 RNA(cfRNA),已成为液体活检应用中生物标志物的有前途的候选物。虽然 cfDNA 存在重大挑战,但研究人员已将注意力转向 cfRNA,cfRNA 可以通过各种方法有效地识别,被认为是癌症诊断和预后的潜在生物标志物。本综述主要关注检测体液中各种 cfRNA 作为生物标志物的研究。目的是提供可用信息的摘要,以帮助研究人员进行研究并开发新的诊断和预后工具。